
Metformin: clinical use in type 2 diabetes
, Volume 60, Issue9 , pp 15861593 | Cite as
Metformin: clinical use in type 2 diabetes
Metformin is one of the most popular oral glucose-lowering medications, widely considered to be the optimal initial therapy for patients with type 2 diabetes mellitus. Interestingly, there still remains controversy regarding the drugs precise mechanism of action, which is thought to involve a reduction in hepatic glucose production. It is now recommended as first-line treatment in various guidelines, including that of the EASD and ADA. Its favoured status lies in its efficacy, low cost, weight neutrality and good safety profile. Other benefits have also been described, including improvements in certain lipids, inflammatory markers, and a reduction in cardiovascular events, apparently independent from the drugs glucose-lowering effect. Data have emerged questioning the previous reluctance to use this agent in those with mild to moderate chronic kidney disease. Regulations guiding its use in patients with stable, modest renal dysfunction have, as a result, become more lenient in recent years. With no long-term studies comparing it against newer glucose-lowering drugs, some of which have more robust evidence for cardioprotection, metformins established role as foundation therapy in type 2 diabetes may justifiably be challenged.
BiguanidesGlucose-lowering therapyMetforminReviewType 2 diabetes mellitus
Diabetes Prevention Program Outcomes Study
The online version of this article (doi: 10.1007/s00125-017-4336-x ) contains a slideset of the figures for download, which is available to auth
Continue
reading